Finalist Teams Awarded $1 Million in XPrize Healthspan Contest to Transform Healthy Aging

The XPrize Healthspan—which will split $101 million among teams developing therapeutics to restore muscle, cognitive, and immune function in older adults—has named 10 teams receiving $1 million each.

(XPrize announced the finalists for its XPrize Healthspan competition | XPrize)

The XPrize Healthspan competition has named its top 20 finalist groups that will submit their aging intervention therapies for human trial testing.

Aging &amp; Longevity

<div class="qMYqUG_convSearchResultHighlightRoot">
<div class="" data-turn-id-container="request-WEB:358025a4-babd-4cd5-8368-0989249581f5-4" data-is-intersecting="true">
<section class="text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:358025a4-babd-4cd5-8368-0989249581f5-4" data-turn-id-container="request-WEB:358025a4-babd-4cd5-8368-0989249581f5-4" data-testid="conversation-turn-10" data-turn="assistant">
<div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)">
<div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn" data-conversation-screenshot-content="">
<div class="flex max-w-full flex-col gap-4 grow">
<div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" dir="auto" tabindex="0" data-message-author-role="assistant" data-message-id="b889d53a-36fb-4739-ae44-5127c67b0f7b" data-message-model-slug="gpt-5-5" data-turn-start-message="true">
<div class="flex w-full flex-col gap-1 empty:hidden">
<div class="markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling">
<p class="PDq2pG_selectionAnchorContainer" data-start="0" data-end="125">Model: 4-week-old <span class="hover:entity-accent entity-underline inline cursor-pointer align-baseline"><span class="whitespace-normal">SM/J</span></span> mice (with <span class="hover:entity-accent entity-underline inline cursor-pointer align-baseline"><span class="whitespace-normal">C57BL/6J</span></span> comparison mice)</p>
<p data-start="127" data-end="279" data-is-last-node="" data-is-only-node="">Dosage: Weekly intraperitoneal injections of 40 mg/kg Navitoclax or 5 mg/kg Dasatinib + 50 mg/kg Quercetin from 4 to 6–8 or 17 weeks of age.</p>
</div>
</div>
</div>
</div>
<div class="z-0 flex min-h-[46px] justify-start"></div>
<div class="mt-3 w-full empty:hidden">
<div class="text-center"></div>
</div>
</div>
</div>
</section>
</div>
</div>
<div class="pointer-events-none -mt-px h-px translate-y-[calc(var(--scroll-root-safe-area-inset-bottom)-14*var(--spacing))]" aria-hidden="true"></div>


Dasatinib and Quercetin Delay Early-Onset Disc Degeneration in Mice

Researchers find that clearing senescent cells preserves disc structure and slows early-onset disc degeneration in mice.


<p>Model: Six adults who received intravenous NAD+ and eight adults who received intravenous NR</p>
<p>Dosage: 500 mg of intravenous NAD+ or 500 mg of intravenous NR daily for four consecutive days</p>


Pilot Human Study Supports Safety of NAD+ IV and NR IV Infusions

A Stanford study supports the short-term safety of NAD+ and NR infusion therapies, and participants who received NR infusions exhibited significantly lower HbA1c (a blood test that reflects average blood sugar over two to three months).

(An IV bag containing a solution with NAD+ | Crete Fertility Centre)

A Stanford human trial provides the first data supporting the safety of NAD+ IV and NR IV therapies.

Cellular reprogramming, an innovative age-reversal technology, stimulates the regeneration of heart cells after a heart attack in mice. 

Cardiovascular

What Is Mosaic Aging? How Organs Age at Different Rates

A new framework proposes that the patchwork nature of aging, where different organs deteriorate at different speeds, may hold the key to understanding the ultimate cause of death.

(University of Glasgow logo | Scotland.org)

A new framework proposes that aging occurs unevenly in cells, tissues, and organs, and that targeting the fastest-aging tissues may extend lifespan.

Search Result: Red Light Therapy

10 Finalist Teams Awarded $1 Million in XPrize Healthspan Contest to Transform Healthy Aging

Dasatinib and Quercetin Delay Early-Onset Disc Degeneration in Mice

Pilot Human Study Supports Safety of NAD+ IV and NR IV Infusions

New Age-Reversing Tech Helps Heart Regenerate, Scientists Find

What Is Mosaic Aging? How Organs Age at Different Rates